BARDA DRIVe ImmuneChip+ (through
Supports creators of immune-enabled organ-on-chip systems and biosensing manufacturing for critical health technology challenges.
The BARDA DRIVe ImmuneChip+ program is an open Broad Agency Announcement (BAA) administered by the Biomedical Advanced Research and Development Authority's Division of Research, Innovation, and Ventures, accepting proposals on a rolling basis through September 28, 2028. The program funds advanced in vitro microphysiological systems — commonly known as organ-on-chip platforms — that incorporate immune components, targeting applications in chemical, biological, radiological, and nuclear (CBRN) medical countermeasure development. The solicitation is catalogued as Area of Interest 10.0 under the main BARDA BAA (BAA-23-100-SOL-00004) and uses the EZ-BAA submission format via the bdr.hhs.gov portal.
Eligible applicants include for-profit companies, nonprofit organizations, universities, and other research organizations operating in the United States; individual applicants are not eligible. The program specifically targets platforms featuring automated manufacturing capabilities, integrated biosensors, and multi-tissue integration — capabilities designed to advance MCM testing beyond traditional animal models. Award amounts, page limits, and detailed evaluation criteria are contained in SAM.gov PDF attachments associated with the solicitation. Pre-submission inquiries may be directed to ImmunechipBARDA@hhs.gov.
Organizations pursuing this opportunity should monitor bdr.hhs.gov for the current solicitation documents, as specific funding levels, proposal requirements, and scoring rubrics are embedded in the PDF attachments rather than on the landing page. Given the continuous acceptance window through September 2028, teams can submit at any time, allowing applicants to refine concepts and align submissions with their technology readiness milestones. The instrument is a procurement contract, not a grant, which means SBIR-style data rights provisions do not apply — applicants should review the BAA terms governing intellectual property before submission.
Advanced in vitro microphysiological systems incorporating immune components — including organ-on-chip platforms with automated manufacturing, biosensors, and multi-tissue integration — for CBRN medical countermeasure development.
Sign up free to see the funding breakdown
Sign up free to see the industries in scope
Sign up free to see the full eligibility
Sign up free to see the timeline